Global Tuberculosis Vaccine Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tuberculosis Vaccine Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.
Tuberculosis Vaccine Treatment report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tuberculosis Vaccine Treatment market is projected to reach US$ 91 million in 2034, increasing from US$ 74 million in 2022, with the CAGR of 2.9% during the period of 2024 to 2034. Demand from Self-Procurement and UNICEF are the major drivers for the industry.
In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.
The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.
Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.
Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tuberculosis Vaccine Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Self-Procurement
UNICEF
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tuberculosis Vaccine Treatment market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tuberculosis Vaccine Treatment, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tuberculosis Vaccine Treatment industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tuberculosis Vaccine Treatment in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tuberculosis Vaccine Treatment introduction, etc. Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Tuberculosis Vaccine Treatment market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.
Tuberculosis Vaccine Treatment report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tuberculosis Vaccine Treatment market is projected to reach US$ 91 million in 2034, increasing from US$ 74 million in 2022, with the CAGR of 2.9% during the period of 2024 to 2034. Demand from Self-Procurement and UNICEF are the major drivers for the industry.
In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.
The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.
Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.
Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tuberculosis Vaccine Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Segment by Application
Self-Procurement
UNICEF
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tuberculosis Vaccine Treatment market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tuberculosis Vaccine Treatment, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tuberculosis Vaccine Treatment industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tuberculosis Vaccine Treatment in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tuberculosis Vaccine Treatment introduction, etc. Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Tuberculosis Vaccine Treatment market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices